



AMENDMENTS TO THE CLAIMS

1. (Previously amended) A compound having the formula (I):



and salts thereof;

wherein R is:



wherein X and X'' are independently selected from C=O, C=S, C=NH, C=NR^x, S=O or SO₂;

wherein n is 1;

wherein R^x is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is X''R^y, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is H, NH_2 , NHR^A , $NR^A R^B$, heteroaryl, cycloalkyl or heterocyclyl;


wherein R^A and R^B are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

provided that when B is H and X is C=O, then A is other than

(a) a pyridinyl ring substituted with a single $NHC(O)R^D$ substituent or

(b) a (C_5-C_6) saturated cycloalkyl ring substituted with a single $NHC(O)R^D$ substituent, wherein R^D is (C_1-C_{17}) unsubstituted alkyl or (C_2-C_{17}) unsubstituted alkenyl;

wherein R^1 is



wherein X' and X''' are independently selected from C=O, C=S, C=NH, C=NR^X, S=O or SO₂;

wherein m is 0 or 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;


wherein B' is $X'''R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH₂, NHR^{A'}, NR^{A'}R^{B'}, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^{A'} and R^{B'} are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R⁵⁰-R⁵³ is independently selected from C₁-C₁₅ alkyl;


alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R² is



wherein K and K' together form a C₃-C₇ cycloalkyl or heterocyclyl ring or a C₅-C₁₀ aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,



wherein each of R^{24} , R^{25} , and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or


alternatively, wherein J, together with R^{17} , forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18} , forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and




wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,




wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.

2. (Previously amended) A compound having the formula (I):



and salts thereof;

wherein R is:



wherein X and Xⁿ are independently selected from C=O, C=S, C=NH, X, S=O or SO₂;

wherein n is 1;

wherein R^x is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is X^mR^Y , H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl,

heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;


wherein A is aryl;

provided that when B is H and X is C=O, then A is other than a phenyl ring substituted with either:

(a) -O-((C₈-C₁₅) unsubstituted alkyl), wherein said phenyl ring may be further optionally substituted with one substituent selected from halo, nitro, (C₁-C₃) alkyl, hydroxyl, (C₁-C₃) alkoxy or (C₁-C₃) alkylthio; or

(b) -NHC(O)R^D, wherein the phenyl ring may be further optionally substituted with 1-2 substituents independently selected from amino, nitro, (C₁-C₃) alkyl, hydroxyl, (C₁-C₃) alkoxy, halo, mercapto, (C₁-C₃) alkylthio, carbamyl or (C₁-C₃) alkylcarbamyl, wherein R^D is (C₁-C₁₇) unsubstituted alkyl or (C₂-C₁₇) unsubstituted alkenyl;

wherein R¹ is



wherein X' and X''' are independently selected from C=O, C=S, C=NH, C=NR^X, S=O or SO₂;

wherein m is 0 or 1;

wherein R^X is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is X''R^Y, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;


wherein R^Y is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH₂, NHR^{A'}, NR^{A'}R^{B'}, alkyl, alkenyl, alkynyl, alkoxy,

aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50} - R^{53} is independently selected from C_1 - C_{15} alkyl;


alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is



wherein K and K' together form a C_3 - C_7 cycloalkyl or heterocyclyl ring or a C_5 - C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J , $NR^J R^K$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,




wherein each of R^{24} , R^{25} , and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or


alternatively, wherein J, together with R^{17} , forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

alternatively, wherein J, together with both R^{17} and R^{18} , forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and




wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,



wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.


Claims 3-4 (Withdrawn)

C2
5. (Currently amended) The compound according to ~~either of claims claim 1 or 2,~~
wherein R is selected from the group consisting of:




wherein each of R³, R⁴, R⁵, and R⁶ is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R²⁰⁰ is selected from the group consisting of hydrido, aryl, heterocyclyl, and heteroaryl.

6. (Currently amended) The compound according to claim 5, wherein R is selected from




02
Cachde
and wherein R⁴ is selected from the group consisting of substituted phenyl, heteroaryl, and heterocyclyl.


7. (Currently amended) The compound according to claim 6, wherein R is selected from the group consisting of



wherein X³ is chloro or trifluoromethyl and wherein q is 0



8. (Previously amended) The compound according to either of claims 1 or 2, wherein R¹ is selected from the group consisting of:



wherein R^8 is selected from a natural amino acid side chain or an amino acid side chain that is not naturally occurring;

wherein each of R^9 , R^{10} and R^{11} is selected from hydrido, alkyl, aryl, heterocyclyl and heteroaryl;


wherein R^{12} is selected from the group consisting of heterocyclyl, heteroaryl, aryl, and alkyl and

wherein R^{13} is selected from (C_1 - C_3 -alkyl) and aryl.

C3

9. (Currently amended) The compound according to claim 8, wherein R^1 is selected from the group consisting of:

OB
agachale




wherein R^8 is selected from tryptophan side chain and lysine side chain;
wherein each of R^{10} and R^{11} is independently selected from hydrido and alkyl;


wherein R^{12} is selected from imidazolyl, N-methylimidazolyl, indolyl, quinolinyl, benzyloxybenzyl, and benzylpiperidenylbenzyl; and

wherein X^4 is selected from fluoro, and trifluoromethyl.

10. (Previously amended) The compound according to either of claims 1 or 2, wherein J is selected from the group consisting of hydrido, amino, azido and




wherein R^{17} and R^{18} taken together form a group selected from ketal,




or wherein R^{17} is hydroxyl when R^{18} is hydrido;

or wherein J, together with R^{17} , forms a heterocyclyl ring.


11. (Original) The compound according to claim 10, wherein R^2 is selected from the group consisting of




wherein R^{17} and R^{18} taken together form a group selected from



, wherein R^{22} is selected from the group consisting of H and alkyl; and wherein R^{19} is selected from the group consisting of hydrido, amino,



12. (Original) The compound according to claim 11, wherein R^2 is



Claims 13-14 (Cancelled)

15. (Previously amended) A pharmaceutical composition comprising the compound according to either of claims 1 or 2 and a pharmaceutically acceptable carrier.

Claims 16-22 (Withdrawn)

23. (Currently amended) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents including sulfonamides, trimethoprim and its combinations and, pyrimethamine, synthetic antibacterials including nitrofurans, methenamine mandelate and methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, ~~everminomycin~~, everminomicin, glycopeptide, ~~glycylcysteine~~, glycylicycline, ketolides, ~~oxazolidinone~~, oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, Ziracin (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-

hexopyranosyl)flambamycin), LY333328 (oritavancin), CL-331002, HMR3647,
 Linezolid (N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-
 oxazolidinyl]methyl]acetamide), Synercid (dalbapristin-guinupristin), Aztreonam (2-
 [[(Z)-[1-(2-amino-4-thiazolyl)-2-[[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidiny] amino]-
 2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), Metronidazole (2-methyl-5-nitro-
 1H-imidazole-1-ethanol), Epiroprim (5-[[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-
 2,4-pyrimidinediamine), OCA-983 (1-[[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-
 anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-
 azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253
 (trinem), Sanfetrinem sodium ((1S, 5S, 8aS, 8bR)-1, 2, 5, 6, 7, 8, 8a, 8b-octahydro-1-
 [(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-
 834 ((4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3R)-5-oxo-3-
 pyrrolidinyl]thio]-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-
 oxopropoxy)methyl ester), Biapenem (6-[[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-
 hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6, 7-dihydro-5H-
 pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), A-99058.1, A-165600, A-179796, KA 159
 (stipiamide), Dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13, 14-hexahydro-
 6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-
 [3]hexene[1,5]diynonaphtho[2,3-c]phenanthridine-2-carboxylic acid), DX8739
 ((4R,5S,6S)-3-[[[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-oxopentyl]-1-
 piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-
 azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[[(6S)-6,7-
 dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-
 1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid), Cefluprenam ((2E)-N-(2-amino-2-
 oxoethyl)-3-[(6R,7R)-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)](fluoro
 methoxy)imino]acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-


N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), Cefoselis ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), Sanfetrinem celextetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl]oxy]ethyl ester), HGP-31, Cefpirome (1-[[[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl][4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), Mersacidin, KP 736 ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)][[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin VIII), Kesan, AM-1732, MEN 10700 ((5R,6S)-3-[[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), Lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3'S,4S)-[2,3'-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), NE-1530 (3'-sialyllacto-N-neotetraose), PR 39 (L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-

prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-
prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolyl-L-phenylalanyl-L-prolyl-L-
prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-
prolinamide [SEQ ID NO: 1]), K130 (5-[[4-[3-[[4-[(4-
aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl] methyl]-2,4-
pyrimidinediamine), OPC 20000, OPC 2045, Venoprim, PD 138312 ((R)- 7-[3-(1-amino-
1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-
naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-
pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-
carboxylic acid), CP 111905 (5-deoxy-5-[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-
2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene-D-neo-inositol), Sulopenem
((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-
4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-
[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788
((6R,7R)- 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-
[(3'R)-1'-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-
3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
monosodium salt), Cycloethialidine, Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-
dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-
1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28, 29,41,42-octadecahydro-41-hydroxy-12,45-
bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-
51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nona-18H,27H-
5a,29-(iminoethaniminoethanimino ethaniminoethanimino[7,2]quinolinomethanoxy
methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1',5':1,6]pyrido [3,2-

m[[1,11,17,24,4,7,20, 27]tetrathiatetraazacyclotriacontin-1-yl]carbonyl]-2,3-
 didehydroalanyl-2,3-didehydro-alanine methyl ester stereoisomer), SEP 132613,
 micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-
 (hydroxy-kappa.O)-6-pentylphenyl]-4-thiazolyl-kappa.N3]-3-methyl-4-thiazolidinyl-
 kappa.N3]-2-(hydroxy-kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-
 thiazolecarboxylato(2-)-kappa.N3, kappa.O4]-Zinc), SB-275833, SR-15402
 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-
 pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), SUN-A0026, TOC 39 (1-(2-
 amino-2-oxoethyl)-4-[(1E)-2-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)
 (hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-
 yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-2-[(2S,3S)-2-
 [(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidiny]amino]-1-(2-amino-4-
 thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), Cefozopran (1-[(6R,7R)-7-[(2Z)-
 (5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-
 azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt),
 Cefetamet pivoxil ((6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(methoxy
 imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
 acid (2,2-dimethyl-1-oxopropoxy)methyl ester), and T 3811 (des-F(6)-quinolone).

Claims 24-26 (Withdrawn)

27. (Previously amended) The compound of claim 1 having the formula (II):





























wherein R⁵⁶ is an optionally substituted straight-chain C₈-C₁₄ alkyl group.

Claims 28-29 (Withdrawn)


30. (Previously amended) A method of using the compound according to claim 27 to make a compound according to either of claims 1 or 2.

31. (Previously added) The compound according to either of claims 1 or 2 wherein said compound is selected from









| Cpd # | R | R ¹ | R ² |
|-------|---|-----------------|---|
| 1 | NHCONH(CH ₂) ₇ CH ₃ | NH ₂ |  |

| | | | |
|----|---|--|---|
| 2 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ | NH_2 |  |
| 3 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ |  |  |
| 5 |  |  |  |
| 17 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ |  |  |
| 48 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ | NH_2 |  |
| 56 | $\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$ |  |  |
| 57 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ |  |  |
| 58 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ |  |  |
| 62 | $\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$ |  |  |
| 63 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ |  |  |
| 64 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ |  |  |
| 69 | $\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$ |  |  |
| 70 | $\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$ |  |  |


| | | | |
|-----|--|-----------------|--|
| 71 | NHCONH(CH ₂) ₇ CH ₃ | | |
| 75 | NHCONH(CH ₂) ₁₀ CH ₃ | | |
| 76 | NHCONH(CH ₂) ₇ CH ₃ | | |
| 77 | NHCONH(CH ₂) ₇ CH ₃ | | |
| 78 | NHCONH(CH ₂) ₇ CH ₃ | | |
| 87 | NHCONH(CH ₂) ₁₁ CH ₃ | | |
| 88 | NHCONH(CH ₂) ₁₁ CH ₃ | | |
| 89 | NHCONH(CH ₂) ₁₁ CH ₃ | | |
| 108 | NHCONH(CH ₂) ₁₀ CH ₃ | | |
| 113 | NHCONH(CH ₂) ₁₀ CH ₃ | | |
| 114 | NHCONH(CH ₂) ₁₀ CH ₃ | | |
| 117 | NHCONH(CH ₂) ₈ CH ₃ | NHBoc | |
| 118 | NHCONH(CH ₂) ₈ CH ₃ | NH ₂ | |
| 119 | NHCONH(CH ₂) ₉ CH ₃ | NHBoc | |

| | | | |
|-----|---|---------------|---|
| 120 | $\text{NHCONH}(\text{CH}_2)_9\text{CH}_3$ | NH_2 |  |
|-----|---|---------------|---|

32. (Previously added) The compound according to claim 31 wherein said compound is selected from


| Cpd # | R | R ¹ | R ² |
|-------|--|--|---|
| 2 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ | NH_2 |  |
| 3 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ |  |  |
| 48 | $\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$ | NH_2 |  |
| 89 | $\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$ |  |  |
| 118 | $\text{NHCONH}(\text{CH}_2)_8\text{CH}_3$ | NH_2 |  |
| 120 | $\text{NHCONH}(\text{CH}_2)_9\text{CH}_3$ | NH_2 |  |

33. (New) The compound according claim 2, wherein R is selected from the group consisting of:




wherein each of R^3 and R^5 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R^{200} is aryl.

34. (New) The compound according to claim 33, wherein R is



and wherein R^4 is selected from the group consisting of substituted phenyl.

35. (New) The compound according to claim 34, wherein R is



and wherein X^3 is chloro or trifluoromethyl.

36. (New) The method according to claim 23, wherein anti-folate agents are sulfonamides or synthetic antibacterials are selected from nitrofurans, methenamine mandelate and methenamine hippurate.
